Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study

MT Newswires Live01-31

Jupiter Neurosciences (JUNS) said Thursday that it has entered into a partnership with Zina Biopharmaceuticals for an upcoming phase 2a clinical trial to evaluate Jupiter's Jotrol resveratrol-based platform in Parkinson's disease.

Zina will assist with trial design, regulatory strategy, and trial site selection, according to Jupiter.

The study has a primary objective of evaluating the safety and tolerability of Jotrol, with secondary endpoints to assess the drug's pharmacokinetics and pharmacodynamics, Jupiter said.

Jupiter also said it is exploring partnerships to look into Jotrol's potential for treating other neuroinflammatory and metabolic disorders, including Alzheimer's disease.

Shares of Jupiter were down more than 5% in recent trading.

Price: 1.15, Change: -0.07, Percent Change: -5.74

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2507675983?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-31 01:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2507675983","market":"hk","top_or_hot":-1,"title":"Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/JUNS\">Jupiter Neurosciences</a> (JUNS) said Thursday that it has entered into a partnership with Zina Biopharmaceuticals for an upcoming phase 2a clinical trial to evaluate Jupiter's Jotrol resveratrol-based platform in Parkinson's disease.</p><p>Zina will assist with trial design, regulatory strategy, and trial site selection, according to Jupiter.</p><p>The study has a primary objective of evaluating the safety and tolerability of Jotrol, with secondary endpoints to assess the drug's pharmacokinetics and pharmacodynamics, Jupiter said.</p><p>Jupiter also said it is exploring partnerships to look into Jotrol's potential for treating other neuroinflammatory and metabolic disorders, including Alzheimer's disease.</p><p>Shares of Jupiter were down more than 5% in recent trading.</p><p>Price: 1.15, Change: -0.07, Percent Change: -5.74</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-01-31 01:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/JUNS\">Jupiter Neurosciences</a> (JUNS) said Thursday that it has entered into a partnership with Zina Biopharmaceuticals for an upcoming phase 2a clinical trial to evaluate Jupiter's Jotrol resveratrol-based platform in Parkinson's disease.</p><p>Zina will assist with trial design, regulatory strategy, and trial site selection, according to Jupiter.</p><p>The study has a primary objective of evaluating the safety and tolerability of Jotrol, with secondary endpoints to assess the drug's pharmacokinetics and pharmacodynamics, Jupiter said.</p><p>Jupiter also said it is exploring partnerships to look into Jotrol's potential for treating other neuroinflammatory and metabolic disorders, including Alzheimer's disease.</p><p>Shares of Jupiter were down more than 5% in recent trading.</p><p>Price: 1.15, Change: -0.07, Percent Change: -5.74</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2507675983","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2507675983","pubTimestamp":1738256876,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Jupiter Neurosciences  said Thursday that it has entered into a partnership with Zina Biopharmaceuticals for an upcoming phase 2a clinical trial to evaluate Jupiter's Jotrol resveratrol-based platform in Parkinson's disease.Zina will assist with trial design, regulatory strategy, and trial site selection, according to Jupiter.The study has a primary objective of evaluating the safety and tolerability of Jotrol, with secondary endpoints to assess the drug's pharmacokinetics and pharmacodynamics, Jupiter said.Jupiter also said it is exploring partnerships to look into Jotrol's potential for treating other neuroinflammatory and metabolic disorders, including Alzheimer's disease.Shares of Jupiter were down more than 5% in recent trading.Price: 1.15, Change: -0.07, Percent Change: -5.74","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","JUNS":"Jupiter Neurosciences"},"translate_title":"Jupiter Neurosciences与Zina Biopharmaceuticals合作开展帕金森病2a期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JUNS":1},"content_text":"Jupiter Neurosciences (JUNS) said Thursday that it has entered into a partnership with Zina Biopharmaceuticals for an upcoming phase 2a clinical trial to evaluate Jupiter's Jotrol resveratrol-based platform in Parkinson's disease.Zina will assist with trial design, regulatory strategy, and trial site selection, according to Jupiter.The study has a primary objective of evaluating the safety and tolerability of Jotrol, with secondary endpoints to assess the drug's pharmacokinetics and pharmacodynamics, Jupiter said.Jupiter also said it is exploring partnerships to look into Jotrol's potential for treating other neuroinflammatory and metabolic disorders, including Alzheimer's disease.Shares of Jupiter were down more than 5% in recent trading.Price: 1.15, Change: -0.07, Percent Change: -5.74","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2507675983","isCrawlerRequest":true}